SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
jcmm12221-sup-0001-FigS1-S11.pdfapplication/PDF1512K

Figure S1. Schematic representation of the animal model.

Figure S2. TNFSF12 deficiency or anti-TWEAK administration do not significantly alter metabolic parameters.

Figure S3. TNFSF12 deletion decreased vascular damage in 24 weeks-old ApoE KO mice.

Figure S4. TNFSF12 deletion diminished macrophage and foam cells and increased VSMC content in early atherosclerotic plaques from ApoE KO mice.

Figure S5. TNFSF12 deletion diminished T cells content in advanced atherosclerotic plaques from ApoE KO mice.

Figure S6. TNFSF12 deletion or anti-TWEAK administration did not modify proliferation or apoptosis in advanced atherosclerotic plaques of ApoE KO mice.

Figure S7. TNFSF12 deletion diminished pro-inflammatory chemokine expression and NF-κB activation in early atherosclerotic plaques of ApoE KO mice.

Figure S8. TNFSF12 deletion or anti-TWEAK administration diminished TF expression in advanced atherosclerotic plaques of ApoE KO mice.

Figure S9. TNFSF12 deletion or anti-TWEAK administration diminished lesion calcification in brachiocephalic artery of ApoE KO mice.

Figure S10. TNFSF12 deletion or anti-TWEAK administration reduced gelatinase activity in advanced atherosclerotic lesions of ApoE KO mice.

Figure S11. MMP activity is inhibited by MMP inhibitors in the brachiocephalic artery of ApoE KO mice.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.